Olefsky J M
J Clin Invest. 1975 Dec;56(6):1499-1508. doi: 10.1172/JCI108231.
We have studied the in vitro effects of dexamethasone on isolated rat adipocytes at concentrations of dexamethasone therapeutically achieved in man. Glucose oxidation, glucose transport, and insulin binding were assessed. In dexamethasone-treated cells, glucose oxidation was decreased by 30-40% both in the absence of insulin (basal state) and at low insulin levels (less than 25 mu/ML). At maximally effective insulin levels (over 100 muU/ml) no differences existed between control and treated cells. If glucose transport were the rate-limiting step for glucose oxidation in the basal state and at low (submaximal) insulin levels, but not at maximally effective insulin concentrations, then these data could be explained by postulating that dexamethasone has a direct affect on glucose transport and does not affect intracellular oxidative pathways. We tested this hypothesis by directly assessing glucose transport in dexamethasone-treated cells. Glucose transport was assessed by measuring the uptake of [14C]2-deoxy glucose. These studies demonstrated a 30-40% decrease in 2-deoxy glucose uptake by treated cells both in the basal state and at all insulin concentrations. Thus, a direct glucocorticoid effect on the glucose transport system seems to account for the decreased ability of dexamethasone-treated cells to oxidize glucose. Since dexamethasone treatment leads to decreased insulin binding to adipocytes in vivo, we examined the possibility that the in vitro decreases in insulin-mediated glucose transport could be due to decreased insulin receptors. Insulin binding to control and treated adipocytes was measured, and no differences were found. Therefore, in cntrast to previously reported in vivo studies, adipocytes treated in vitro with dexamethasone retain a normal ability to bind insulin. Thus, these studies suggest that all of the in vitro effects of dexamethasone on glucose oxidation are due to direct inhibition of the glucose transport system.
我们研究了地塞米松在人体治疗浓度下对分离的大鼠脂肪细胞的体外作用。评估了葡萄糖氧化、葡萄糖转运和胰岛素结合情况。在地塞米松处理的细胞中,无论是在无胰岛素(基础状态)还是低胰岛素水平(低于25 μU/ml)时,葡萄糖氧化均降低了30 - 40%。在最大有效胰岛素水平(超过100 μU/ml)时,对照细胞和处理细胞之间没有差异。如果葡萄糖转运是基础状态和低(亚最大)胰岛素水平下葡萄糖氧化的限速步骤,但在最大有效胰岛素浓度下不是,那么这些数据可以通过假设地塞米松对葡萄糖转运有直接影响且不影响细胞内氧化途径来解释。我们通过直接评估地塞米松处理细胞中的葡萄糖转运来检验这一假设。通过测量[¹⁴C]2 - 脱氧葡萄糖的摄取来评估葡萄糖转运。这些研究表明,无论是在基础状态还是所有胰岛素浓度下,处理细胞对2 - 脱氧葡萄糖的摄取均降低了30 - 40%。因此,糖皮质激素对葡萄糖转运系统的直接作用似乎可以解释地塞米松处理细胞氧化葡萄糖能力的下降。由于地塞米松处理导致体内胰岛素与脂肪细胞的结合减少,我们研究了体外胰岛素介导的葡萄糖转运减少可能是由于胰岛素受体减少的可能性。测量了胰岛素与对照和处理脂肪细胞的结合情况,未发现差异。因此,与先前报道的体内研究相反,体外用地塞米松处理的脂肪细胞保留了正常的胰岛素结合能力。因此,这些研究表明,地塞米松对葡萄糖氧化的所有体外作用都是由于对葡萄糖转运系统的直接抑制。